Sickle cell disease affects approximately 100,000 people in the United States, predominantly Black and Hispanic Americans, and life expectancy for publicly insured patients remains approximately 52.6 years, roughly 20 years shorter than the general population, even as hydroxyurea therapy and comprehensive care have extended median survival from 14 years in 1973 to as high as 61 years in recent cohorts. As more patients live into the Medicare-age population than in prior decades, accurate genotype-specific coding and complication documentation increasingly determine whether care teams capture the full complexity of adult SCD.
AAVBC's Sickle Cell Anemia Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering HCC/RAF V28 mapping, Medicare Part B covered screenings, subtle early signs in older adults, lifespan complications and transition risks, diagnostic classification, comorbidity screening, MEAT documentation standards, therapy escalation criteria, medication safety in elderly patients with SCD, and coding specificity with case examples. Grounded in current ASH guidance, this guide supports consistent, individualized clinical decision-making, helping care teams document genotype and complications precisely, manage an aging SCD population, and coordinate care with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of sickle cell anemia — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Sickle cell disease affects approximately 100,000 people in the United States, predominantly Black and Hispanic Americans, and life expectancy for publicly insured patients remains approximately 52.6 years, roughly 20 years shorter than the general population, even as hydroxyurea therapy and comprehensive care have extended median survival from 14 years in 1973 to as high as 61 years in recent cohorts. As more patients live into the Medicare-age population than in prior decades, accurate genotype-specific coding and complication documentation increasingly determine whether care teams capture the full complexity of adult SCD.
AAVBC's Sickle Cell Anemia Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering HCC/RAF V28 mapping, Medicare Part B covered screenings, subtle early signs in older adults, lifespan complications and transition risks, diagnostic classification, comorbidity screening, MEAT documentation standards, therapy escalation criteria, medication safety in elderly patients with SCD, and coding specificity with case examples. Grounded in current ASH guidance, this guide supports consistent, individualized clinical decision-making, helping care teams document genotype and complications precisely, manage an aging SCD population, and coordinate care with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of sickle cell anemia — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
